FOXO Technologies Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting total assets of $43,602,941 and total stockholders' equity of just $6,230.

Key Highlights

  • Total assets: $43,602,941 as of September 30, 2026, down from $44,577,873 at December 31, 2025, according to the filing.
  • Total liabilities: $43,596,711, leaving total stockholders' equity of $6,230, compared to $11,076,300 at year-end 2025.
  • Notes payable (current): $12,067,245 as of September 30, 2026, up sharply from $2,151,838 at December 31, 2025.
  • Accumulated deficit: $(217,990,931) as of September 30, 2026, improved from $(224,644,739) at December 31, 2025.
  • Cash and cash equivalents: $42,678 as of September 30, 2026, down from $207,453 at December 31, 2025.
  • Shares outstanding: 1,658,116 shares of Class A common stock as of November 13, 2026, up from 831,887 at December 31, 2025.
  • Going concern: The filing discloses the company's ability to continue as a going concern as a forward-looking uncertainty subject to its cautionary language.

FOXO Technologies Balance Sheet Position for September 30, 2026

According to the quarterly report, FOXO Technologies Inc. (OTC:FOXO), a Delaware corporation operating Healthcare, Life Science Services, and Labs segments with its principal offices in West Palm Beach, Florida, reported total current assets of $4,049,755 at September 30, 2026, compared to $3,112,480 at December 31, 2025. Accounts receivable, net, rose to $3,471,056 from $2,468,346 over the same period. Cash declined to $42,678 from $207,453, the filing disclosed.

On the liabilities side, the company reported total current liabilities of $39,817,932 as of September 30, 2026, up from $28,658,760 at December 31, 2025. The filing shows notes payable within current liabilities increased to $12,067,245 from $2,151,838 at year-end. Related parties' notes and loans payable stood at $5,813,129, while accounts payable grew to $8,756,498 from $6,966,211. The company also reported Medicare cost report settlement payables of $974,342 and accrued contingent purchase price consideration of $107,269 among non-current liabilities.

Goodwill of $26,529,626 and intangible assets, net, of $9,606,750 together comprised the largest share of total assets, the filing indicated. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing also references proposed transactions including a potential acquisition by subsidiary Vector BioSource Inc. of assets of four blood collection centers from Grifols Bio Supplies, Inc., and a proposed acquisition of securities of Ludwig Enterprises, Inc., both of which are described as forward-looking and subject to risks and uncertainties identified in the report.

What Was Disclosed

FOXO Technologies Inc. filed its September 30, 2026 quarterly report disclosing a balance sheet with $43,602,941 in total assets, $43,596,711 in total liabilities, and total stockholders' equity of $6,230, alongside a sharp rise in current notes payable and a decline in cash.